Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma published its audited consolidated and standalone financial results for Q4 and FY ended March 31, 2026 in Financial Express and Jansatta on May 20, 2026. Consolidated revenue grew 17% year-on-year to ₹14,278 Crores in FY26 from ₹12,207 Crores in FY25. However, profit after tax declined slightly to ₹1,938 Crores from ₹2,007 Crores in the prior year. Standalone profit after tax grew to ₹2,038 Crores from ₹1,725 Crores, a robust 18% increase. Basic EPS on consolidated basis stood at ₹46.35 for FY26 versus ₹49.17 in FY25. The Board meeting to approve these results was held on May 19, 2026.
While consolidated revenue growth of 17% is positive, the decline in consolidated profit after tax and EPS suggests margin pressure in the consolidated business. The standalone performance shows stronger profitability improvement, which is a positive signal for the core pharma operations.